课题基金 / 基金详情

POST EXPOSURE PROPHYLAXIS AGAINST HIV 1 BY CD4 IGG2

POST EXPOSURE PROPHYLAXIS AGAINST HIV 1 BY CD4 IGG2
CD4 IGG2 暴露后预防 HIV 1
批准号:
2545220
负责人:
PAUL J MADDON
金额:
$37.52万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-09-30 至 1998-09-29

项目摘要

项目成果

PAUL J MADDON的其他基金

相似基金

相关文献

中文摘要
翻译
在第一阶段的项目中,我们证明了一种新型的基于CD4的蛋白质, CD4-IgG2具有优良的特性,可作为一种新型的 预防HIV-1感染的药物,以保护个人免受 环境中的感染,如垂直和职业接触 病毒。与HIV免疫球蛋白(HIVIG)相比,CD4-IgG2的主要优势 而针对该病毒的单抗是CD4-IgG2中和所有 HIV-1的菌株,包括病毒的初级分离株。在.期间 I期,我们证明了CD4-IgG2在体外中和a 由来自不同基因分支的28个主要HIV-1分离株组成的小组。 此外,CD4-IgG2中和了未稀释的病毒血浆中的HIV-1 体外试验。最后,我们证明了CD4-IgG2对人外周血淋巴细胞的保护作用。 保护SCID小鼠免受HIV-1初级分离株的感染。这是第一次 在动物身上对HIV-1初级分离株的保护作用 使用任何免疫治疗或抗逆转录病毒药物的模型。 在二期项目中,我们将继续开发CD4-IgG2。 首先,我们将扩大生产流程,生产一克 蛋白质。我们将测试CD4-IgG2与广泛性的组合 中和抗HIV-1单抗,协同抑制病毒。 将在两个新的HIV-1信封中分析组合 糖蛋白介导的膜融合实验及体外实验 用HIV-1原代分离株进行中和试验。然后我们将比较 CD4-IgG2单抗与最佳单抗的保护力比较 几种原代HIV-1联合攻击Hu-PBL-SCID小鼠的实验研究 被猿人免疫缺陷挑战的分离株和猕猴 含有HIV-1主要分离株gp120/gp41的病毒(SIV)。 一种安全有效的HIV-1预防性制剂的研制 是一项紧迫的公共卫生优先事项。第二阶段的总体目标 项目是确定CD4-IgG2或CD4-IgG2和 广谱中和单抗,可预防原发感染 在现有的最佳动物模型中分离出HIV-1病毒。如果成功,则 第二阶段项目将成为该阶段临床试验的基础 第三阶段。 拟议的商业应用:开发作为一种 预防HIV-1感染的药物。
英文摘要
In the Phase I project, we demonstrated that a novel CD4-based protein, CD4-IgG2, has excellent properties for further development as a prophylactic agent for HIV-1 infection, to protect individuals from infection in settings such as vertical and occupational exposure to the virus. The major advantage of CD4-IgG2 over HIV immune globulin (HIVIG) and monoclonal antibodies to the virus is that CD4-IgG2 neutralizes all stains of HIV-1, including primary isolates of the virus. During the Phase I period, we demonstrated that CD4-IgG2 neutralized in vitro a panel of 28 primary HIV-1 isolates from different genetic clades. Moreover, CD4-IgG2 neutralized HIV-1 in undiluted viremic plasma in an ex vivo assay. Finally, we demonstrated that CD4-IgG2 protects hu-PBL- SCID mice from infection by primary HIV-1 isolates. This is the first demonstration of protection against primary HIV-1 isolates in an animal model using any immunotherapeutic or antiretroviral agent. In the Phase II project, we will continue the development of CD4-IgG2. First, we will scale-up the production process and generate one gram of the protein. We will test combinations of CD4-IgG2 with broadly neutralizing mAbs to HIV-1 for synergistic inhibition of the virus. Combinations will be analyzed in both a novel HIV-1 envelope glycoprotein-mediated membrane fusion assay and in an in vitro neutralization assay using primary HIV-1 isolates. We will then compare the protective ability of CD4-IgG2 alone versus the optimal CD4-IgG2-mAb combination in hu-PBL-SCID mice challenged with several primary HIV-1 isolates, and macaques challenged with simian-human immunodeficiency virus (SHIV) containing gp120/gp41 of a primary HIV-1 isolate. The development of a safe and effective prophylactic agent against HIV-1 is an urgent public health priority. The overall goal of the Phase II project is to determine whether CD4-IgG2, or combinations of CD4-IgG2 and broadly neutralizing mAbs, can protect against infection by primary isolates of HIV-1 in the best available animal models. If successful, the Phase II project will form the basis of clinical trials during the Phase III period. PROPOSED COMMERCIAL APPLICATION: Development of a CD4-IgG2 as a prophylactic agent against HIV-1 infection.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
CCR5 inhibitors that block HIV but not chemokines
  • 批准号:
    6746752
  • 项目类别:
  • 资助金额:
    $30.36万
  • 财政年份:
    2004
  • 负责人:
    PAUL J MADDON
  • 依托单位:
Development of Small-Molecule HIV Entry Inhibitors
  • 批准号:
    6698946
  • 项目类别:
  • 资助金额:
    $89.94万
  • 财政年份:
    2001
  • 负责人:
    PAUL J MADDON
  • 依托单位:
HIV Vaccine Design and Development Team
  • 批准号:
    6374728
  • 项目类别:
  • 资助金额:
    $209.05万
  • 财政年份:
    2000
  • 负责人:
    PAUL J MADDON
  • 依托单位:
HIV Vaccine Design and Development Team
  • 批准号:
    6348770
  • 项目类别:
  • 资助金额:
    $197.43万
  • 财政年份:
    2000
  • 负责人:
    PAUL J MADDON
  • 依托单位:
海外基金